| Symbol | NGNE |
|---|---|
| Name | NEUROGENE INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 535 W 24 TH STREET,5 TH FLOOR, NEW YORK, New York, 10011, United States |
| Telephone | +1 855 508-3568 |
| Fax | — |
| — | |
| Website | https://www.neurogene.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001404644 |
| Description | Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The companys product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Neurogene Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001104659-26-097193 <b>Size:</b> 13 KB
Read moreNew Form SCHEDULE 13G/A - Neurogene Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001493152-26-038383 <b>Size:</b> 12 KB
Read moreNew Form SCHEDULE 13G - Neurogene Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003430 <b>Size:</b> 15 KB
Read more(90% Positive) NEUROGENE INC. (NGNE) Provides Update on improved for a progressive
Read moreNeurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Read moreNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreDirector Cvijic Christine Mikail 🔴 sold 4.8K shares of Neurogene Inc. (NGNE) at $36.13 Transaction Date: Jul 06, 2026 | Filing ID: 000017
Read moreNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreDirector Cvijic Christine Mikail 🔴 sold 4.8K shares of Neurogene Inc. (NGNE) at $35.23 Transaction Date: Jul 01, 2026 | Filing ID: 000015
Read more